This was significantly higher than that observed in lung adenocarcinomas with an EGFR mutation, with a KRAS mutation but lacking an ALK mutation, or with either an EGFR or KRAS mutation (all P < .005). This evidence concerns the gene KRAS and lung adenocarcinoma.